Ganz, re your 'boost' comment: ....the boost will follow a solid earnings report from VOC sales or a BO.......even some guidance would help regarding some sales numbers.
Assuming no early BO, another bump could come when the final Aurora 2 readout happens.
No one truly knows yet how long these patients should be on the drug (Aurora 2 is blinded with a DSMB).
The readout might cause the analysts who are now around $30 to raise that number.
Patiently waiting here doing nothing might ultimately turn into a major win.